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PANTIPLATELET THERAPY
Slow Response to Clopidogrel Predicts Low Response
Anne Bellemain-Appaix, MD,* Gilles Montalescot, MD, PHD,* Johanne Silvain, MD,*
Olivier Barthélémy, MD,* Farzin Beygui, MD, PHD,* Jean-Philippe Collet, MD, PHD,*
Georges Sideris, MD,† Catherine Meuleman, MD,§ Claire Bal-dit-Sollier, MB,‡
Nicolas Lellouche, MD, Grégory Ducrocq, MD,¶ Michel Slama, MD,# Olivier Milleron, MD,**
Patrick Henry, MD,† Ludovic Drouet, MD, PHD,‡ for the ALBION Investigators
Paris, France
Objectives The purpose of this study was to determine whether the speed of response to clopidogrel loading predicts the
final degree of response.
Background Fast inhibition of platelet aggregation is important in the setting of acute coronary syndromes and percutaneous
coronary intervention, but its association with the final degree of inhibition is not well established.
Methods We performed a post hoc analysis of the ALBION study; early kinetic profiles of adenosine diphosphate 20 mol/l
maximal platelet aggregation (MPA) and MPA (with baseline sample as reference) were studied at 8 time points
within the 24 h after clopidogrel loading (300, 600, or 900 mg) in non–ST-segment elevation acute coronary syn-
drome patients. Low response was defined as MPA 10% over the first 24 h, fast response as MPA 10% at 1 h
or before loading (the others being slow responders), and high post-treatment platelet reactivity as MPA 56.56%
(fourth quartile). Inflammatory markers (PAC-1 and P-selectin) and vasodilator-stimulated phosphoprotein (VASP)
were also evaluated according to onset of action.
Results Fifty-five percent of patients were slow responders. Noncurrent smoking and body mass index 25 kg/m2 were
associated with slower and lower responses. High post-treatment platelet reactivity was more frequent in slow
responders (28% vs. 14%, p  0.0001). There was a clopidogrel dose-effect relationship on MPA, with a trend
toward faster onset of platelet inhibition in the 900-mg loading dose group. Slow responders had a slower and
lower decrease in PAC-1 and P-selectin and higher VASP index at 6 h (76.5% vs. 66.4%, p  0.019) and 24 h
(70.3% vs. 61.5%, p  0.049).
Conclusions Slow response to clopidogrel, within the first hour of administration, is a reliable marker of low response at 24 h
and high post-treatment platelet reactivity. (J Am Coll Cardiol 2010;55:815–22) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.082l
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fast and significant inhibition of platelet function with
lopidogrel is an important goal in patients with acute
oronary syndromes (ACS) (1) and in those undergoing
mergent percutaneous coronary intervention (PCI) (2).
ow response to clopidogrel and high post-treatment plate-
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ssociated with poor clinical outcomes (3,4). However, low
esponse remains time and dose dependent with no consen-
us on its definition (5). The clinical benefit of detection and
orrection may be efficient (6), although still debated. In all
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Clopidogrel Slow Response February 23, 2010:815–22cases, optimal timing between clo-
pidogrel loading and detection re-
mains unclear because this delay
depends on several factors includ-
ing the dose administered (7). In
the setting of ACS or PCI, the
potential association between slow
and low response to clopidogrel
has not been well investigated be-
cause multiple dose samplings are
necessary.
High or very high loading
doses (LDs) of clopidogrel have
been developed mainly to in-
crease the degree of platelet in-
hibition and reduce the variabil-
ity of response to the drug (4,8).
Several studies suggested that
high LDs also reduce the time to
achieve optimal inhibition of
platelet aggregation (9–12), al-
hough divergent results have been published (13). These
tudies typically had a limited number of sampling time
oints and used clopidogrel LDs of600 mg. A few studies
valuated the efficacy and the good tolerance of higher
lopidogrel LDs before PCI (6,7,14), confirming a dose-
ffect relationship with apparently no saturation point in
bsorption or metabolization, at least to LDs of clopidogrel
s high as 900 mg (14).
To address the question of the relationship between slow
nd low responses, we performed a new analysis of the
andomized dose-ranging ALBION (Assessment of the
est Loading Dose of Clopidogrel to Blunt Platelet Acti-
ation, Inflammation and Ongoing Necrosis) study. In this
tudy, 103 non–ST-segment elevation ACS patients were
andomized to receive a clopidogrel loading dose of 300,
00, or 900 mg with multiple sampling time points to
etermine precisely the onset of action and the time of
aximal inhibition of platelet aggregation. In the present
nalysis, we examine the relationship between slow and low
esponses to the drug, not only for platelet aggregation but
lso for platelet activation and markers of inflammation over
he first 24 h after clopidogrel loading.
ethods
tudy design. ALBION was a randomized, parallel-group
tudy of patients hospitalized with non–ST-segment elevation
CS. Study design and methods were described previously (7).
n brief, major inclusion criteria were: 1) age 18 years and
85 years; and 2) ischemic symptoms (onset 48 h) and at
east 1 of the following: electrocardiographic ST-segment or
-wave changes or positive troponin. Major exclusion
riteria were: 1) catheterization performed before random-
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
BMI  body mass index
LD  loading dose
MFI  median fluorescence
intensity
MPA  maximal platelet
aggregation
PCI  percutaneous
coronary intervention
PG  prostaglandin
PPR  post-treatment
platelet reactivity
VASP  vasodilator-
stimulated phosphoproteinzation or scheduled to be performed 24 h after random- 0zation; and 2) contraindication of the use of low-molecular-
eight heparin, clopidogrel, or acetylsalicylic acid.
Using central randomization, patients were allocated to
eceive a clopidogrel LD of 300, 600, or 900 mg orally on
he morning of day 1 of the study. All patients received an
D of 250 to 500 mg of aspirin and low molecular weight
eparin twice daily.
ssay methods. Aggregometry and flow cytometry were
rocessed in a core laboratory that was blinded to the
reatment received at all time points over the 24 h, with a
aseline sample before any clopidogrel administration.
DENOSINE DIPHOSPHATE (ADP)-INDUCED PLATELET
GGREGATION. Platelet aggregation was induced by the
ddition of ADP (Chrono-Par, Kordia, the Netherlands) at
final concentration of 20 mol/l; parameters were mea-
ured on samples obtained at baseline and 0.5, 1, 2, 3, 4, 5,
, and 24 h. Variation of maximal platelet aggregation
MPA [percentage]) at time Tx was: (intensity of aggre-
ation at T baseline)  (intensity of aggregation at Tx).
LOW CYTOMETRY. PAC-1 and P-selectin flow cytometry
easurements were done on samples obtained at baseline
nd 0.5, 1, 2, 3, 4, 5, 6, and 24 h. Platelet activation markers
ere measured after stimulation of platelets with ADP
5 mol/l final concentration).
The phosphorylation of vasodilator-stimulated phos-
hoprotein (VASP) was measured at 6 and 24 h. The
ASP index was calculated from the median fluorescence
ntensity (MFI) of samples incubated with prostaglandin
PG) E1 and ADP according to the formula: VASP index
(MFI(PGE1)  MFI(PGE1ADP))/MFI(PGE1)]  100.
nd points. The objective of the current analysis was to
etermine whether an initial slow response to loading dose
as related to a low response or to high PPR when the
lateau effect was reached. The main analysis was the
hange in maximal inhibition of platelet aggregation in-
uced by 20-mol/l ADP (MPA %MPAtx %MPA
0 %), which was calculated with the baseline sample (t0).
he very early kinetic profile of clopidogrel-mediated
MPA was studied. Slow response was defined as MPA
10% within the first hour after loading. Low response was
efined as MPA 10% over the whole 24-h period.
ost-treatment platelet reactivity (PPR) was defined for
ach patient as the lowest value of MPA obtained over the
4-h period of observation; patients with high PPR were
hose in the fourth quartile of the distribution of PPR
alues.
As a secondary objective of the study we studied the
ssociation between slow response (as described above) and the
inetics of inhibition of platelet activation. Inhibition of
latelet activation was evaluated by: 1) activated glycoprotein
Ib/IIIa receptor complexes (PAC-1) (PAC-1  PAC-1
0  PAC-1 Tx); 2) P-selectin (P-selectin  Psel t0 
sel Tx); and 3) P-VASP (VASP index  VASP index
0  VASP index Tx=); at the different time points of Tx
.5, 1, 2, 3, 4, 5, 6, and 24 h after LD; Tx=  6 and 24 h.
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February 23, 2010:815–22 Clopidogrel Slow Responsetatistical analyses. Data were analyzed using SAS soft-
are (SAS Institute, Cary, North Carolina). Normality of
esiduals was assessed by the Shapiro-Wilk test. Qualitative
ariables were compared using the Pearson chi-square test
r the Fisher exact test. The time course of the change from
aseline to the maximum intensity of platelet aggregation
nduced by ADP was compared using an analysis of variance
t each time point without correction. MPAs were com-
ared using an analysis of variance with a confirmatory
nalysis by the Mann-Whitney U test when the hypothesis
f homogeneity of variance was not verified. The platelet
ctivation parameters were analyzed using the same model
f analysis of variance but after log transformation of the
umber of epitopes. Multivariate analysis was done on
ariables that reached the p  0.10 threshold after univar-
ate analysis (logistic regression model with simultaneous
ntry of variables). Correlations were done using the Pear-
on correlation coefficient. Results are reported with mean
nd SD or number and percentage as appropriate. A p value
0.05 was considered significant.
esults
latelet aggregation. Patients with low clopidogrel re-
ponse are represented on the far left of the gaussian curve
f MPA (Fig. 1). The mean MPA was 0.3  3.1%
n low responders versus 15.3  10.2% in the other patients
p  0.0001).
Slow responders were the patients whose MPA did not
each the 10% threshold within the first hour of clopidogrel
oading. Baseline demographic characteristics of slow and
ast responders are presented in Table 1. Active smoking
as associated with a fast response to clopidogrel. A higher
MPA after the clopidogrel LD was found in smokers
mean MPA of 17.9  11.8% in smokers vs. 12.1 
0.8% in nonsmokers, p  0.0201), and none of the active
Figure 1
Distribution Curve of Variation in
Maximal Platelet Aggregation (%, 20-mol/l
Adenosine Diphosphate) Over the Whole 24-h Period
Patients with low response to clopidogrel with variation in maximal
platelet aggregation 10% are represented on the far left of the curve.imokers were found to be a clopidogrel low responder. A
igh body mass index (BMI) was associated with a slow
esponse to clopidogrel: 58.6% of overweight patients (BMI
25 kg/m2) were slow responders and 11.4% were low
esponders compared with 46% and 3.8%, respectively, in
atients with BMI 25 kg/m2. There was a 1.6 odds ratio
or slow response (95% confidence interval: 0.96 to 2.64,
 0.0525) and 1.45 odds ratio for low response (95%
onfidence interval: 0.76 to 2.75, p  0.2756) for each
-kg/m2 increment of BMI (Table 2). However, after
ultivariate analysis (that included BMI and smoking in
ddition to other variables), we did not identify any clinical
ariables independently or significantly correlated with the
peed of response to clopidogrel.
Twenty-five percent (n  21) of patients had high PPR
56.56%, fourth quartile). High PPR was more frequent
n slow responders than in fast responders (28% vs. 14%,
espectively; p  0.0001) and (78% vs. 16%, p  0.0001) in
ow responders versus good responders.
The relationship between slow and low response is shown
n Figure 2. The early difference in MPA between slow
nd fast responders remained stable over time (p  0.0001
t each time point), with a plateau reached at the fifth hour
aseline Characteristics oflow Versus F s Responders (n  96)Table 1 B elin Characteristics ofSlow Versus Fast Responders (n  96)
Slow Fast p Value
n 53 (55%) 43 (45%)
Age (yrs) 63.7 12.5 59.3 11.4 0.0824
Male sex 41 (77%) 35 (81%) 0.6282
Risk factors
Tobacco use 11 (21%) 18 (42%) 0.0251
High blood pressure 35 (66%) 20 (47%) 0.0544
Hyperlipidemia 30 (57%) 21 (49%) 0.4483
Diabetes 15 (28%) 6 (14%) 0.0908
Body mass index (kg/m2) 27.8 5.0 25.6 3.3 0.0141
Nitrates 19 (36%) 18 (42%) 0.5473
Aspirin chronic 25 (47%) 13 (30%) 0,0915
Beta-blockers 42 (79%) 32 (74%) 0.5758
Calcium-channel blockers 16 (30%) 9 (21%) 0.304
Statin 36 (68%) 25 (58%) 0.3219
Cyp 27 (75%) 19 (76%) 0.9289
Electrocardiogram (%)
ST-segment depression 15 (28%) 17 (40%) 0.2456
Biology
Serum creatinine (m/l) 108 66 100 75 0.5688
Platelets (10*102/mm3) 232.4 60 240.7 48.6 0.4655
Neutrophils (10*102/mm3) 5,720 3,535 5,584 2,655 0.8515
Hemoglobin (g/l) 138.8 17.4 135.8 16.6 0.3982
Troponin (g/l) 1.8 2.6 2.3 5.4 0.5915
Clopidogrel loading dose
300 mg 19 (36%) 14 (33%) 0.4874
600 mg 19 (36%) 12 (28%)
900 mg 15 (28%) 17 (39%)
alues are n (%) or mean  SD. Cyp (means Cytochrome P450 3A4 metabolized statins) are:
torvastatin (59% of cyp in slow responders, 53% in fast responders, p  0.7299) and
imvastatin. Bold p values indicate significance (p  0.05) in univariate analysis.n both groups. Even when the 9% of patients with a low
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Clopidogrel Slow Response February 23, 2010:815–22esponse were excluded from this analysis, the relationship
emained similar and significant, with a clear association
etween the initial onset of response and the final magni-
ude of response. As initially described for inhibition of
latelet aggregation (7), we found in this analysis a signif-
cant dose-effect relationship of clopidogrel LD on MPA
nd MPA. A similar but nonsignificant trend was also
ound for the onset of response, with slow responders
ending to be less frequent in the 900-mg group than in the
ther 2 groups (p  NS).
latelet activation. Slow clopidogrel responders showed a
ower reduction in platelet membrane expression of PAC-1
nd P-selectin, resulting in smaller constant and significant
hanges of PAC-1 and P-selectin compared with fast
esponders, as shown in Figures 3 and 4. The VASP index,
hich calculates the relative ADP-dependent inhibition of
he platelet adenylate cyclase pathway, was no different
mong the groups at baseline. There was a positive and
ignificant correlation between MPA and VASP index
t 6 h (r  0.39, p  0.0003). Slow responders had a
igher VASP index than fast responders at 6 h (76.5% vs.
epartition of Low and Slow Response According BMI GroupTable 2 Repartition of Low and Slow Response According BMI
BMI (kg/m2)
Low Responders Resp
OR (95% CI) % (n) %
25 Reference 3.8% (1) 96.2
25–30 2.42 (0.26–22.7) 8.3% (4) 91.7
30 5.78 (0.6–55.56) 18.2% (4) 81.8
Total 9.3% (9) 90.6
dds ratio (OR) is shown by body mass index (BMI) category (25 kg/m2 as reference).
CI  confidence interval.
Figure 2 Kinetics of MPA ADP 20 mol/l Slow/Fast
Relationship between the onset of action and magnitude of response (MPA [ADP
mean  SD). *p  0.0001. ADP  adenosine diphosphate; MPA  variation in6.4%, p  0.019) and 24 h (70.3% vs. 61.5%, p  0.049)
Table 3).
iscussion
ow clopidogrel response has become a relevant concern in
CI and ACS because of its association with clinical
utcomes (3,4). Because of the lack of a consensus, numer-
us definitions of low response have been used (using
arious techniques, devices, agonists, index calculations,
hresholds, timing of blood sampling, and clopidogrel treat-
ent), with subsequent variations in analysis and interpre-
ation of this issue (Fig. 5). It remains that the clopidogrel
ffect is poorly predictable and that persistent high PPR to
reatment is predictive of further ischemic events. Some
linical factors have been associated with high PPR (diabe-
es mellitus [15–17], obesity [15,16], nonsmoking [17]), as
ell as some drug interactions (lipophilic statins [18],
alcium inhibitors [19], proton pump inhibitors such as
meprazole [20]), high basal platelet reactivity (21), and
enetic factors (CYP2C19*2 carriers [22]), but are not used
p
s Slow Responders Fast Responders
OR (95% CI) % (n) % (n)
) Reference 46.2% (12) 53.8% (14)
) 1.12 (0.44–2.9) 52.1% (25) 47.9% (23)
) 2.87 (0.86–9.6) 72.7% (16) 27.3% (6)
) 55.2% (55) 44.8% (43)
ol/l]
al platelet aggregation.Grou
onder
(n)
% (25
% (44
% (18
% (8720 m
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February 23, 2010:815–22 Clopidogrel Slow Responses isolated predictive factors for low clopidogrel response.
e demonstrate here that the assessment of the response to
lopidogrel within the first hour after loading may identify
atients with a final poor response to the drug. We also
how that active smoking, known to facilitate clopidogrel
ctivation (23) and reduce clopidogrel resistance (3,21), also
ccelerates platelet inhibition by clopidogrel; high BMI, a
nown factor for low response (probably through a decrease
f CYP450 3A4 activity) is also a factor for slow response in
ur population. However, multivariate analysis suggests that
Figure 3 Kinetics of PAC-1 Fast Versus Slow
Kinetics of PAC-1 (adenosine diphosphate [ADP] 5 mol/l, mean  SD) accordin
Figure 4 Kinetics of P-Selectin Fast Versus Slow
Kinetics of P-selectin (adenosine diphosphate 5 mol/l, mean  SD) accordinghese clinical factors are interrelated when measuring the
nhibitory effect of clopidogrel.
The unique design of the ALBION study with multiple
ampling time points similar to a phase 1 study, allowed us
o study the relationship between the onset and the magni-
ude of effect. The definition of slow response comes from
mechanistic model validated in healthy volunteers after a
00-mg clopidogrel LD (24). This model showed that an
nitial slope of MPA 20%/h (defined as slow response)
as associated with clopidogrel nonresponse (defined as
e type of response (slow vs. fast response). *p  0.05.
type of response (slow vs. fast response). *p  0.05.g to thto the
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Clopidogrel Slow Response February 23, 2010:815–22MPA 15% at 4, 5, or 24 h) and was strongly correlated
ith MPA 15% at 1 h or less. The rate of slow
esponders to clopidogrel was 46% (median 8%/h decrease
ate in MPA, with 75% of them being low responders),
hereas a median 33%/h decrease rate in MPA was found
n the 54% of fast responders. Fifty-five percent of slow
esponders (using a more restrictive and easier threshold of
0% MPA with 2 time points of 1 h or less) confirm these
esults in ACS patients, with slightly lower rates of decrease
n MPA in both groups (fast and slow responders).
Platelet activation findings supported our data. P-selectin
nd PAC-1 have been associated with more frequent
schemic events after PCI (25), and the slow decrease of
hese markers might be an early indicator of a persistent
roinflammatory and prothrombotic state. The VASP in-
ex, a specific measure of the P2Y12 platelet ADP receptor
athway inhibition by clopidogrel, has already been used to
VASP Index According to the Initial Response (STable 3 VASP Index According to the Initial
Time
Slow
n Mean (SD)
6 h 50 76.4 (15.8)
24 h 50 70.3 (22.2)
VASP  vasodilator-stimulated phosphoprotein; LSMEANS  least sig
Figure 5 Incidence of Low Clopidogrel Response According to
For references shown in Figure 5, please see the Online Appendix.redict low clopidogrel response (26), high PPR (27), and
isk of ischemic event and stent thrombosis after PCI (28);
e show here that slow and low clopidogrel response can be
etected with light transmission aggregometry and the
ASP index. Because the bedside test VerifyNowP2Y12 is
orrelated with these 2 methods (29,30), early (within 1 h of
oading) and easy assessment of clopidogrel response might
e done, if decided, in current practice.
Previous studies based on clopidogrel low response have
uggested that tailored antiplatelet therapy could improve
schemic outcomes in some situations such as stent throm-
osis with demonstrated biological resistance (by a switch
rom clopidogrel to prasugrel [31]), in non–ST-segment
levation ACS patients who underwent PCI (by the use of
nti-glycoprotein IIb and IIIa [32]), but also in elective PCI
atients (by clopidogrel reloading [6,14]). However, there is
o consensus on such a strategy yet, and it needs to be
vs. Fast)onse (Slow vs. Fast)
Fast
Difference of LSMEANS
(Slow vs. Fast) p ValueMean (SD)
66.4 (20.3) 0.0192
61.5 (19.1) 0.0492
means.
us Definitions Used in the LiteraturelowResp
n
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February 23, 2010:815–22 Clopidogrel Slow Responseurther explored and probably restricted for the time being
o the higher-risk patients. Furthermore, platelet inhibition
ith prasugrel in ACS patients was slower than expected
rom previous data in healthy volunteers (24,33), leading us
o believe that the speed of response to prasugrel could also
ary from patient to patient.
tudy limitations. The present study has the limitations of
post-hoc analysis, performed with biological end points.
he definition used here that needs a baseline sample for
eference might be difficult to apply in some patients (ACS
atients urgently treated or patients under long-term ther-
py). However, our results suggest that platelet reactivity
easured rapidly after loading is a good indicator of later
esponse. Finally, it remains to be shown whether slow
esponse, just like low response, bears a higher ischemic risk,
hether tailored antiplatelet treatment leads to clinical
enefits, and whether fast responders are exposed to an
ncreased risk of bleeding.
onclusions
low clopidogrel response is a reliable indicator of low
lopidogrel response in ACS patients, but whether early
etection and correction of slow clopidogrel response are
linically relevant remains to be shown.
eprint requests and correspondence: Dr. Gilles Montalescot,
nstitut de Cardiologie, Bureau 2-236, Pitié-Salpêtrière Hospital,
7 Boulevard de l’Hôpital, 75013 Paris, France. E-mail: gilles.
ontalescot@psl.aphp.fr.
EFERENCES
1. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel
pretreatment before percutaneous coronary intervention in patients
with ST-elevation myocardial infarction treated with fibrinolytics: the
PCI-CLARITY study. JAMA 2005;294:1224–32.
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with
clopidogrel and aspirin followed by long-term therapy in patients
undergoing percutaneous coronary intervention: the PCI-CURE
study. Lancet 2001;358:527–33.
3. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in
patients with acute myocardial infarction. Circulation 2004;109:
3171–5.
4. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose
of clopidogrel on platelet reactivity and clinical outcomes in patients
with non-ST-segment elevation acute coronary syndrome undergoing
coronary stenting. J Am Coll Cardiol 2006;48:1339–45.
5. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce
platelet reactivity and activation following standard dosing in elective
stenting: implications for thrombotic events and restenosis. Platelets
2004;15:9–59.
6. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel
loading doses according to vasodilator-stimulated phosphoprotein
phosphorylation index decrease rate of major adverse cardiovascular
events in patients with clopidogrel resistance: a multicenter random-
ized prospective study. J Am Coll Cardiol 2008;51:1404–11.
7. Montalescot G, Sideris G, Meuleman C, et al. A randomized
comparison of high clopidogrel loading doses in patients with non-
ST-segment elevation acute coronary syndromes: the ALBION (As-
sessment of the Best Loading Dose of Clopidogrel to Blunt Platelet
Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll
Cardiol 2006;48:931–8.8. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio
G. Randomized trial of high loading dose of clopidogrel for reduction
of periprocedural myocardial infarction in patients undergoing coro-
nary intervention: results from the ARMYDA-2 (Antiplatelet therapy
for Reduction of MYocardial Damage during Angioplasty) study.
Circulation 2005;111:2099–106.
9. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose
of clopidogrel on platelet function in patients undergoing coronary
stent placement. Heart 2001;85:92–3.
0. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of
platelet inhibition after a 600-mg loading dose of clopidogrel in a
large, unselected cohort of candidates for percutaneous coronary
intervention. Circulation 2005;111:2560–4.
1. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US.
Clopidogrel loading with eptifibatide to arrest the reactivity of plate-
lets: results of the Clopidogrel Loading With Eptifibatide to Arrest
the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation
2005;111:1153–9.
2. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of
clopidogrel. Semin Thromb Hemost 1999;25 Suppl 2:3–8.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel
loading dose during coronary stenting: effects on drug response and
interindividual variability. Eur Heart J 2004;25:1903–10.
4. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel
reloading in patients already on 75-mg maintenance dose: the Reload
with Clopidogrel Before Coronary Angioplasty in Subjects Treated
Long Term with Dual Antiplatelet Therapy (RELOAD) study.
Circulation 2008;118:1225–33.
5. Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and
diabetes mellitus are associated with lower inhibition of platelet
reactivity with clopidogrel. J Am Coll Cardiol 2008;52:1052–9.
6. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and
clopidogrel responses in acute coronary syndrome and clinical predic-
tors of non response. Thromb Res 2009;123:597–603.
7. Motovska Z, Widimsky P, Petr R, et al. Factors influencing clopi-
dogrel efficacy in patients with stable coronary artery disease undergo-
ing elective percutaneous coronary intervention: statin’s advantage and
the smoking “paradox.” J Cardiovasc Pharmacol 2009;53:368–72.
8. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the
ability of clopidogrel to inhibit platelet aggregation: a new drug-drug
interaction. Circulation 2003;107:32–7.
9. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel
blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol
2008;52:1557–63.
0. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump
inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost
2009;101:714–9.
1. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for
coronary stenting: response variability, drug resistance, and the effect of
pretreatment platelet reactivity. Circulation 2003;107:2908–13.
2. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymor-
phism in young patients treated with clopidogrel after myocardial
infarction: a cohort study. Lancet 2009;373:309–17.
3. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette
smoking with enhanced platelet inhibition by clopidogrel. J Am Coll
Cardiol 2008;52:531–3.
4. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of
speed of onset of platelet inhibition after loading doses of clopidogrel
versus prasugrel in healthy volunteers and correlation with responder
status. Am J Cardiol 2007;100:331–6.
5. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane
activation markers are predictive for increased risk of acute ischemic
events after PTCA. Circulation 1993;88:37–42.
6. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopy-
ridines: clinical detection of coronary stent thrombosis by monitoring
of vasodilator-stimulated phosphoprotein phosphorylation. Catheter
Cardiovasc Interv 2003;59:295–302.
7. Cuisset T, Frere C, Quilici J, et al. Lack of association between the 807
C/T polymorphism of glycoprotein Ia gene and post-treatment plate-
let reactivity after aspirin and clopidogrel in patients with acute
coronary syndrome. Thromb Haemost 2007;97:212–7.
8. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet
reactivity in patients with stent thrombosis: results of the CREST
study. J Am Coll Cardiol 2005;46:1827–32.
23
3
3
3
K
F
822 Bellemain-Appaix et al. JACC Vol. 55, No. 8, 2010
Clopidogrel Slow Response February 23, 2010:815–229. Morel O, Viellard C, Faure A, et al. [Platelet responsiveness to
clopidogrel in patients with coronary syndrome. Comparison of
platelet aggregation induced by ADP and flow cytometric analysis of
intraplatelet VASP phosphorylation]. Ann Cardiol Angiol (Paris)
2007;56:21–9.
0. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibi-
tion after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer:
the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb
Res 2007;119:277–84.
1. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel
resistance? Circulation 2009;119:2854–7.
2. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet
inhibition with tirofiban in poor responders to aspirin, clopidogrel, or
both agents undergoing elective coronary intervention: results from the Fdouble-blind, prospective, randomized Tailoring Treatment with Ti-
rofiban in Patients Showing Resistance to Aspirin and/or Resistance to
Clopidogrel study. Circulation 2009;119:3215–22.
3. Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Pharmacody-
namic assessment of platelet inhibition by prasugrel vs. clopidogrel in
the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753–63.
ey Words: acute coronary syndromes y clopidogrel y platelets.
APPENDIX
or the additional references shown in
igure 5, please see the online version of this article.
